These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 23294453)

  • 1. A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation.
    Alai M; Lin WJ
    J Microencapsul; 2013; 30(6):519-29. PubMed ID: 23294453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation.
    Alai M; Lin WJ
    AAPS J; 2014 May; 16(3):361-72. PubMed ID: 24519468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of HPMC and Eudragit S100 blended microparticles containing sodium pantoprazole.
    Raffin RP; Colomé LM; Haas SE; Jornada DS; Pohlmann AR; Guterres SS
    Pharmazie; 2007 May; 62(5):361-4. PubMed ID: 17557744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: in vitro and in vivo evaluations.
    Alai M; Lin WJ
    Int J Nanomedicine; 2015; 10():4029-41. PubMed ID: 26124659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease.
    Castell D; Bagin R; Goldlust B; Major J; Hepburn B
    Aliment Pharmacol Ther; 2005 Jun; 21(12):1467-74. PubMed ID: 15948814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
    Heyman MB; Zhang W; Huang B; Chiu YL; Amer F; Winter HS
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):35-40. PubMed ID: 17204950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of gastroretentive raft forming systems incorporating curcumin-Eudragit® EPO solid dispersions for gastric ulcer treatment.
    Kerdsakundee N; Mahattanadul S; Wiwattanapatapee R
    Eur J Pharm Biopharm; 2015 Aug; 94():513-20. PubMed ID: 26143367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of mixture design for formulation of albumin containing enteric-coated spray-dried microparticles.
    Shastri PN; Ubale RV; D'Souza MJ
    Drug Dev Ind Pharm; 2013 Feb; 39(2):164-75. PubMed ID: 22591196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin.
    Wu ZM; Zhou L; Guo XD; Jiang W; Ling L; Qian Y; Luo KQ; Zhang LJ
    Int J Pharm; 2012 Apr; 425(1-2):1-8. PubMed ID: 22248666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of anti-GERD activity of gastro retentive drug delivery system of itopride hydrochloride.
    Satapathy T; Panda PK; Goyal AK; Rath G
    Artif Cells Blood Substit Immobil Biotechnol; 2010 Aug; 38(4):200-7. PubMed ID: 20515421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel nanoparticulate system for sustained delivery of acid-labile lansoprazole.
    Alai MS; Lin WJ
    Colloids Surf B Biointerfaces; 2013 Nov; 111():453-9. PubMed ID: 23867305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
    Morgan D; Pandolfino J; Katz PO; Goldstein JL; Barker PN; Illueca M
    Aliment Pharmacol Ther; 2010 Jul; 32(2):200-8. PubMed ID: 20456300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Freeze dried chitosan/ poly-(glutamic acid) microparticles for intestinal delivery of lansoprazole.
    Singh MN; Yadav HK; Ram M; Shivakumar HG
    Curr Drug Deliv; 2012 Jan; 9(1):95-104. PubMed ID: 21864257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and characterization of enteric microparticles by coacervation.
    Thomas S; Chong YN; Chaw CS
    Drug Dev Ind Pharm; 2013 Jul; 39(7):1142-51. PubMed ID: 23003201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteric controlled-release pantoprazole-loaded microparticles prepared by using Eudragit S100 and poly(epsilon-caprolactone) blend.
    Raffin RP; Colomé LM; Guterres SS; Pohlmann AR
    Pharm Dev Technol; 2007; 12(5):463-71. PubMed ID: 17963146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
    Behm BW; Peura DA
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.